You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US.
The firm said today that it received a notice that it is out of compliance with a rule requiring timely filings with the US Securities and Exchange Commission.
The company missed analyst estimates on the top line, but beat expectations for loss per share during the quarter.
The company posted a 3 percent increase in molecular diagnostics sales at constant exchange rates, and a 3 percent decline in instrument sales.
The company, which beat Wall Street expectations on the top and bottom lines, said completed Cologuard test volume rose 150 percent over Q1 2016.
The company reported $4.77 billion in first quarter revenues, driven by growth in all of its business segments.
The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.
The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.
Of the $295 million to $305 million in revenues expected in 2017, Luminex executives said that around $45 million should come from automated MDx sales.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.